Page 6 - Ancer Immunotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MyNEO Therapeutics to focus on building proprietary product pipeline based on a novel class of shared therapeutic cancer targets derived from the dark genome named “camyotopes” Lead product CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccineCAMYO-01 is advancing towards clinical development for the treatment of colorectal cancer GHENT, Belgium – October 25th 2023. myNEO, a biotech company focused on exploiting “dark genome” targets to devel

In this interview, Grace Liu from Sino Biological discusses the crucial role of biomarkers in cancer prevention and diagnosis and how they can help guide treatment decisions.

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker is keen to restore Roche's battered drug development record after major late-stage tria...

ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker

A "two-for-one" cancer immunotherapy is potentially more effective and at least as safe as standard immunotherapies, physician-scientists from UPMC Hillman Cancer Center who led an international, early-phase clinical trial report today in the journal Nature Medicine.